Sara Tolaney· @stolaney1 · X·· 2 天前评分90
正文 · 原文
NATALEE: OS data
Adjuvant ribociclib in ER+ breast cancer
6 yr OS HR 0.809 (delta 2.1%)
BCSS: 0.706 (delta 2.6%)
6 yr iDFS HR 0.741 (delta ~5%)
DDFS: HR 0.744
@OncoAlert #ESMO26
2056 浏览 · 15 赞 · 11 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org来源：Sara Tolaney · x.com